Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q8NB37
UPID:
GALD1_HUMAN
Alternative names:
Parkinson disease 7 domain-containing protein 1
Alternative UPACC:
Q8NB37; B7ZKW5; Q2NL76; Q6ZQY0; Q8NAE0
Background:
Glutamine amidotransferase-like class 1 domain-containing protein 1, also known as Parkinson disease 7 domain-containing protein 1, plays a crucial role in cellular processes. Its unique structure and alternative names highlight its significance in biological systems.
Therapeutic significance:
Understanding the role of Glutamine amidotransferase-like class 1 domain-containing protein 1 could open doors to potential therapeutic strategies. Its involvement in cellular mechanisms makes it a key target for drug discovery efforts.